MetaCap

Inhibikase Therapeutics (IKT) vs Sutro Biopharma (STRO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sutro Biopharma (STRO) has outperformed Inhibikase Therapeutics (IKT) over the past year, gaining 2.4% versus a loss of 11.4%. Over five years, IKT leads with a -89.3% price change compared with -94.7% for STRO. Inhibikase Therapeutics is the larger company by market cap ($185.2 million vs $142.8 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IKT-11.41%STRO+2.38%
+407%+187%-33%
Nov 21, 20251 yearNov 20, 2026
IKT-88.42%STRO-95.10%
+14%-44%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IKT versus STRO key metrics
MetricIKTSTRO
Share price$1.32$8.60
Market cap$185.16M$142.77M
1-day change+1.54%-1.38%
YTD return-35.61%-25.67%
1-year return-11.41%+2.38%
5-year return-89.32%-94.68%
EPS (TTM)$-0.40$-12.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$102.48M
Revenue growth (YoY)—+65.18%
Net income (latest FY)$-48.26M$-191.09M
Operating margin—-154.53%
Net margin—-186.45%
52-week high$2.61$43.85
52-week low$1.28$7.15
Distance from 52-week high-49.43%-80.39%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+320.45%+419.65%
Average volume584.27K304.90K
Shares outstanding140.27M16.60M
Employees35129
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • STRO has outperformed IKT by 13.8 percentage points over the past year.

About Inhibikase Therapeutics

IKT stock →

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees

About Sutro Biopharma

STRO stock →

Sutro Biopharma, Inc. operates as an oncology company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 129 employees

IKT vs STRO FAQ

Which is bigger, Inhibikase Therapeutics or Sutro Biopharma?

Inhibikase Therapeutics (IKT) is larger, with a market capitalization of $185.16M compared with $142.77M for Sutro Biopharma (STRO).

Which stock has performed better over the past year, IKT or STRO?

STRO returned +2.38% over the past 12 months, compared with -11.41% for IKT (price return, excluding dividends). Past performance does not predict future results.

Are Inhibikase Therapeutics and Sutro Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons